Almac launches GMP peptide manufacturing facility in Scotland

| By | Drug Manufacturing, GMP Standards
0
70

Almac Group, the global contract development and manufacturing organisation, is delighted to announce the successful MHRA registration of its High Throughput GMP Peptide manufacturing facility.

Based at the Technopole campus near Edinburgh, Scotland, the facility manufactures neoantigen derived peptides for use in the production of patient specific, individualised cancer vaccines.

Speed is critical within this therapeutic context as the entire supply chain is focused on minimising “needle to needle” time – i.e. the time between the initial patient biopsy and the ultimate vaccine administration. Almac Sciences’ experts have been associated with the individualised cancer vaccine field for several years and its facility and systems have been set up to enable fully GMP compliant manufacture and release of 20-30 GMP peptides within less than three weeks.

Almac has manufactured multiple High Throughput batches of neoantigen derived peptides –branded by Almac as NeoPeptides™ – for compassionate use treatments, and for P-I clinical trials, from its Edinburgh facility. Over the course of the past ten months the facility has been upgraded and segregated to enable GMP supply. A bespoke Pharmaceutical Quality System has been designed and implemented to enable high speed, fully compliant GMP manufacture. The systems have now been tested through a number of Pivotal Engineering Runs and have demonstrated robust performance and the ability to consistently achieve the less than three weeks peptide manufacturing target. GMP supply is expected to commence in Quarter 3, 2018.

SOURCE: almac
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.